Publications & Patents

1.      Cellular immune breadth of an Omicron-specific, self-amplifying monovalent mRNA vaccine booster for COVID-19

npj Vaccines. 2025; 10(42). doi: 10.1038/s41541-025-01076-2

2.     LmCen-/- based vaccine is protective against canine visceral leishmaniasis following three natural exposures in Tunisia

npj Vaccines. 2025: 10(31). doi: 10.1038/s41541-025-01070-8

3.     Purification of T7 RNA polymerase for large scale production of mRNA vaccines and therapeutics

Process Biochem. 2024 Dec; 147():391-401. doi:10.1016/j.procbio.2024.10.005

4.    Prospective Observational Cohort Study of Tenecteplase: Results From the Indian Registry in Ischemic Stroke-Tenecteplase

J Am Heart Assoc. 2024 Dec 3;13(23):e036382. doi: 10.1161/JAHA.124.036382.

5.     Augmenting the landscape of chimeric antigen receptor T-cell therapy

Expert Rev. Anticancer Ther. 2024 Aug; 24(8):755-773. doi:10.1080/14737140.2024.2372330

6.     Manufacturing and preclinical toxicity of GLP grade gene deleted attenuated Leishmania donovani parasite vaccine

Sci Rep. 2024; 14:14636. doi:10.1038/s41598-024-64592-6

7.     Combinative workflow for mRNA vaccine development

Biochem Biophys Rep. 2024 June 25; 39: 101766. doi: 10.1016/j.bbrep.2024.101766.

8.    An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial

Nat Med. 2024 May;30(5):1363-1372. doi: 10.1038/s41591-024-02955-2.

9.     Leveraging the immunoinformatics approach for designing the SARS-CoV-2 omicron-specific antigenic cassette of mRNA vaccine

Vaccine. 2024 Mar 7;42(7):1630-1647. doi: 10.1016/j.vaccine.2024.01.087

10.  Production of leishmanin skin test antigen from Leishmania donovani for future reintroduction in the field

Nat Commun. 2023 Nov 2; 14(1): 7028. doi: 10.1038/s41467-023-42732-2. 

11.   Evaluation of self-amplifying mRNA platform for protein expression and genetic stability: Implication for mRNA therapies

Biochem Biophys Res Commun. 2023 Nov 5:680:108-118. doi: 10.1016/j.bbrc.2023.09.016.

12.  Systematic clinical and pharmacological monitoring of a PEG-asparaginase biogeneric (HAMSYL) in paediatric patients with newly-diagnosed acute lymphoblastic leukaemia

Pediatr Hematol Oncol. 2023; 8(4:S48. doi: 10.1016/j.phoj.2023.10.122

13.  Vaccine for leishmaniasis: New era of CRISPR generated Live attenuated dermotropic Leishmania

J Cell Mol Med. 2022 Mar 21; 1(1):12-16. doi: 10.46439/immunol.1.004.

14.  Translational development of a tumor junction opening technology

Nature. 2022 May 11; Scientific Reports; Article number: 7753 (2022).

15.  Development of a process for large scale production of PfRH5 in E. coli expression system.

Int J Biol Macromol. 2021 Aug 6;188:169-179. doi: 10.1016/j.ijbiomac.2021.08.014.

16.  Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis.

Commun Biol. 2021 Jul; 4(1):929. doi: 10.1038/s42003-021-02446-x.

17.   Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia.

Pediatr Blood Cancer. 2021; 3;e29046. doi:10.1002/pbc.29046.

18.  Insights into interplay of immunopathophysiological events and molecular mechanistic cascades in psoriasis and its associated comorbidities.

J Autoimmun. 2021; 118:102614. doi: 10.1016/j.jaut.2021.102614 

1. The Plasmodium falciparum circumsporozoite protein produced in Lactococcus lactis is pure and stable.

J Biol Chem. 2020 Jan 10;295(2):403-414. doi: 10.1074/jbc.RA119.011268.

2. Randomized, Parallel Group, Open-Label Bioequivalence Trial of Intramuscular Pegaspargase in Patients With Relapsed Acute Lymphoblastic Leukemia

JCO Glob Oncol. 2020 Jul:6:1009-1016. doi: 10.1200/GO.20.00113.

3. Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials

Am J Cardiovasc Drugs. 2018 Oct;18(5):387-395. doi: 10.1007/s40256-018-0284-1.

4. Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial.

NPJ Vaccines. 2018 Sep 28;3:48. doi: 10.1038/s41541-018-0083-3.

5. The Leishmania donovani IMPACT-like protein possesses non-specific nuclease activity.

Int J Biol Macromol. 2018 Nov;119:962-973. doi: 10.1016/j.ijbiomac.2018.07.175.

6. Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity

Pediatr Hematol Oncol. 2018 Aug-Sep;35(5-6):331-340. doi: 10.1080/08880018.2018.1538277.

7. Retrospective post-marketing study on the use of bio-similar pegasparagase among acute lymphoblastic leukemia patients in India

Pediatr. Hematol. Oncol. J. 2018:3(1):9-12. doi: 10.1016/j.phoj.2018.03.001.

8. Activation of HRI is mediated by Hsp90 during stress through modulation of the HRI-Hsp90 complex.

Int J Biol Macromol. 2018 Oct 15;118(Pt B):1604-1613. doi: 10.1016/j.ijbiomac.2018.06.204.

9. Elucidation of molecular mechanism of stability of the heme-regulated eIF2α kinase upon binding of its ligand, hemin in its catalytic kinase domain.

J Biomol Struct Dyn. 2018 Aug;36(11):2845-2861. doi: 10.1080/07391102.2017.1368417.

10. HRI, a stress response eIF2α kinase, exhibits structural and functional stability at high temperature and alkaline conditions.

Int J Biol Macromol. 2017 Feb;95:528-538. doi: 10.1016/j.ijbiomac.2016.11.071.

11. Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection.

NPJ Vaccines. 2017;2. pii: 10. doi: 10.1038/s41541-017-0011-y.

12. Pharmacological Reperfusion Therapy with Tenecteplase in 7,668 Indian Patients with ST Elevation Myocardial Infarction – A Real World Indian Experience

J Assoc Physicians India. 2017 Sep;65(9):43-47.

13. Assessing analytical comparability of biosimilars: GCSF as a case study

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 1:1032:165-171. doi: 10.1016/j.jchromb.2016.05.027.

1. Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants.

Malar J. 2015 Nov 9;14:443. doi: 10.1186/s12936-015-0972-0.

2.Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): report of an international collaborative study.

J Immunol Methods. 2015 Jan:416:17-28. doi: 10.1016/j.jim.2014.10.005.

3. Association of antibodies to Plasmodium falciparum reticulocyte binding protein homolog 5 with protection from clinical malaria.

Front Microbiol. 2014 Jun 30;5:314. doi: 10.3389/fmicb.2014.00314.

4. Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice.

Infect Immun. 2013 Mar;81(3):789-800. doi: 10.1128/IAI.01108-12.

5. Pharmacologic Reperfusion Therapy with Indigenous Tenecteplase in 15,222 patients with ST Elevation Myocardial Infarction – The Indian Registry

Indian Heart J. 2013 Jul-Aug;65(4):436-41. doi: 10.1016/j.ihj.2013.06.010.

6. Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies.

Infect Immun. 2012 Mar;80(3):1203-8. doi: 10.1128/IAI.05924-11.

7. Nrf2 regulates hyperoxia-induced Nox4 expression in human lung endothelium: identification of functional antioxidant response elements on the Nox4 promoter.

Free Radic Biol Med. 2011 Jun 15;50(12):1749-59. doi:10.1016/j.freeradbiomed.2011.03.022.

8. Tenecteplase in the treatment of acute pulmonary thrombo-embolism

J Thromb Thrombolysis. 2011 May;31(4):445-8. doi: 10.1007/s11239-010-0524-y.